Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2

Complete if Known				
Application Number	10/559,982			
Filing Date	February 2, 2006			
First Named Inventor	Ruggero FARIELLO			
Group Art Unit	1627			
Examiner Name	JAVANMARD, Sahar			
Confirmation No.	6583			
Attorney Docket No.	373987-011US (102895)			

U.S. PUBLISHED DOCUMENTS					
Examiner	Cite	U.S. Publica	tion Document		Date of Publication of
Initials*	No.1	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY

	,		FOR	EIGN PA	TENT DOCUM	MENTS		
Examiner	Cite	Fore	eign Patent Docu	ıment	Date of		Transla	ition <sup>2</sup>
Initials*	No. 1	Office	Number	Kind Code (if known)	Publication of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Yes	No

Examiner Initials*	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		Translation <sup>2</sup>	
	No. 1			No	
	C109	OLANOW et al., "The scientific and clinical basis for the treatment of Parkinson disease (2009)," <i>Neurology</i> , Vol. 72 (Supple 4), pp. S1-S136 (2009). (Exhibit A to Second Declaration of C. Warren Olanow Under 37 C.F.R. § 1.132)			
	C110	OLANOW et al., "Modeling Parkinson's Disease," <i>Annals of Neurology</i> , Vol. 66, no. 4, pp. 432-436 (2009). (Exhibit B to Second Declaration of C. Warren Olanow Under 37 C.F.R. § 1.132)			
	C111	OLANOW et al., "An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment Guidelines," <i>American Academy of Neurology</i> , Vol. 56, pp. S1-S88 (2001). (Exhibit C to Second Declaration of C. Warren Olanow Under 37 C.F.R. § 1.132)			

	the second secon	 	44/44/44
Examiner	/Sahar Javanmard/	Date Considered	03/06/2010
Signature	/Janai Javaninaiu/	Dute Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2

Complete if Known			
Application Number	10/559,982		
Filing Date	February 2, 2006		
First Named Inventor	Ruggero FARIELLO		
Group Art Unit	1627		
Examiner Name	JAVANMARD, Sahar		
Confirmation No.	6583		
Attorney Docket No.	373987-011US (102895)		

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate),	Transl	ation
Initials*	No. 1	title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Yes	No
	C112	MCCALL et al., "Sumanirole, a Highly Dopamine D <sub>2</sub> -Selective Receptor Agonist: In Vitrol and in Vivo Pharmacological Characterization and Efficacy in Animal Models of Parkinson's Disease," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 314, no. 3, pp. 1248-1256 (2005). (Exhibit D to Second Declaration of C. Warren Olanow Under 37 C.F.R. § 1.132)		

	Examiner	Sohar Jayanmard	Date Considered	AN IONI NO 4 O
1	Signature	/Sahar Javanmard/		03/06/2010

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation or translation of abstract is attached.